Completed PHASE1 INTERVENTIONAL 3-arm NCT05793450

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Interventions IBI362

Updated 5 times since 2023 Last updated: Feb 18, 2024 Started: May 5, 2023 Primary completion: Sep 18, 2023 Completion: Nov 17, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Renal Impairment and is currently completed. Innovent Biologics (Suzhou) Co. Ltd. leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2023 — Mar 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Apr 2023 — Jun 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innovent Biologics (Suzhou) Co. Ltd.

Data source: Innovent Biologics (Suzhou) Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China